EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real‐life experience of luspatercept in transfusion‐dependent lower risk myelodysplastic syndrome patients

Anthi Bouchla iD, Sotirios G Papageorgiou iD, Ioannis Kotsianidis, Panagiotis Diamantopoulos iD, Eleni Gavriilaki iD, Eleni Bouronikou, Argiris Symeonidis iD, Panagiotis Zikos, Mustafa Cetiner, Efthymia Vlachaki, Akrivi Kostourou, Athanasios Galanopoulos und 13 weitere

British Journal of Haematology · 2025-07 · 207 (1) · 101-109

DOI: 10.1111/bjh.20102 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 05.05.2025. Verfasst von Anthi Bouchla und 24 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine and Research Institute, Hematology Unit, Attikon University Hospital, National and Kapodistrian University of Ath…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Recombinant Fusion Proteins, Immunoglobulin Fc Fragments, Activin Receptors, Type II. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Luspatercept has been approved for the treatment of anaemia in transfusion‐dependent (TD) patients with lower risk (LR) myelodysplastic syndromes (MDS) after erythroid‐stimulated agent (ESA) failure, according to the results of the MEDALIST trial. In this multicentre retrospective study, we report efficacy and safety data of luspatercept administered in 98 TD LR‐MDS patients after ESA failure. The percentage of patients that stopped luspatercept due to adverse events was comparable to that reported in the MEDALIST study. Furthermore, we observed that 44.3% patients who had completed 24 weeks of follow‐up achieved transfusion independence lasting longer than 8 weeks, compared to 38% in the MEDALIST trial. These positive results may be attributed to the inclusion of patients with lower transfusion needs in our study. All responses were observed within 8 months since luspatercept onset and many were long‐lasting, even in the high‐transfusion burden patient group. In addition, response to luspatercept and the presence of less than two mutations independently predicted for longer overall survival. Overall, our results confirm luspatercept's safety and efficacy in TD LR‐MDS patients who have experienced ESA failure in a real‐world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsActivin Receptors, Type IIBlood TransfusionHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAdultTreatment Outcome

Stichwörter der Autor:innen

lower risk MDSluspaterceptresponsesurvivaltransfusion dependence

Substanzen

luspaterceptRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsActivin Receptors, Type II

Autor:innen und Institutionen

  • 2nd Department of Internal Medicine and Research Institute, Hematology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
  • Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Hematology Department BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
  • Department of Hematology, University Hospital of Larissa, Larissa, Greece.
  • Department of Hematology, University General Hospital of Patras, Patras, Greece.

ORCID-Profile: Anthi Bouchla, Sotirios G Papageorgiou, Panagiotis Diamantopoulos, Eleni Gavriilaki, Argiris Symeonidis, Eleftheria Hatzimichael, Maria Mainou, Vasiliki Pappa

Zitieren

APA

Bouchla, A., Papageorgiou, S. G., Kotsianidis, I., Diamantopoulos, P., Gavriilaki, E., Bouronikou, E., Symeonidis, A., Zikos, P., Cetiner, M., Vlachaki, E., Kostourou, A., Galanopoulos, A., Hatzimichael, E., Vervesou, E. C., Bozdağ, S. C., Viniou, N. A., Christoulas, D., Dellatola, M., Papaioannou, M., …, & Pappa, V. (2025). Real‐life experience of luspatercept in transfusion‐dependent lower risk myelodysplastic syndrome patients. British Journal of Haematology, 207(1), 101-109. https://doi.org/10.1111/bjh.20102

Vancouver

Bouchla A, Papageorgiou SG, Kotsianidis I, Diamantopoulos P, Gavriilaki E, Bouronikou E, et al. Real‐life experience of luspatercept in transfusion‐dependent lower risk myelodysplastic syndrome patients. British Journal of Haematology. 2025;207(1):101-109. doi:10.1111/bjh.20102

BibTeX
@article{Bouchla2025,
  author = {Bouchla, Anthi and Papageorgiou, Sotirios G and Kotsianidis, Ioannis and Diamantopoulos, Panagiotis and Gavriilaki, Eleni and Bouronikou, Eleni and Symeonidis, Argiris and Zikos, Panagiotis and Cetiner, Mustafa and Vlachaki, Efthymia and Kostourou, Akrivi and Galanopoulos, Athanasios and Hatzimichael, Eleftheria and Vervesou, Elisavet-Christina and Bozdağ, Sinem Civriz and Viniou, Nora-Athina and Christoulas, Dimitrios and Dellatola, Maria and Papaioannou, Maria and Papoutselis, Menelaos and Vlachopoulou, Dimitra and Syrigou, Antonia and Mainou, Maria and Chatzileontiadou, Sofia and Pappa, Vasiliki},
  title = {Real‐life experience of luspatercept in transfusion‐dependent lower risk myelodysplastic syndrome patients},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {1},
  pages = {101--109},
  doi = {10.1111/bjh.20102}
}
Kostenlos starten →